TrialsgrambêtaRCTs are beautiful
ESC Congress 2026Présenté ven. 28 août · 11:15 UTC+2Hot Line 1Tous les essais Hot Line →

SINGLE-AF

2026

The Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Intermediate Stroke Risk in Patients With Atrial Fibrillation

In 1,803 patients with atrial fibrillation at intermediate stroke risk, a direct oral anticoagulant reduced the net composite of stroke, embolism, major bleeding and death at 2 years compared with no anticoagulation.

Résultat

Efficacité: Composite of stroke, systemic embolism, ISTH major bleeding and cardiovascular death at 2 yearsHR 0,31 (IC à 95 % 0,10-0,94) · P = 0,03

En dessous de 1 en faveur de a direct oral anticoagulant, au-dessus de 1 en faveur de no anticoagulation.

Taux d’événements
Différence absolue
1,0 points
NNT
100

La différence absolue et le NNT sont dérivés des taux d’événements.

Également rapporté: Driven by ischaemic stroke (0.1% vs 1.1%). Major bleeding 0.3% vs 0.5%.

Publication originale
Sous-thème
Stroke prevention
Schéma
Investigator-initiated, multicentre, open-label, superiority RCT with blinded outcome adjudication (PROBE), 1:1, permuted blocks stratified by centre, 24-month follow-up, South Korea
Pertinence
Important: l’un des piliers parmi d’autres.
Source
Kim D, Lee Y, et al. N Engl J Med. 2026; published online 28 August.doi 10.1056/nejmoa2607978

Discussion et critique

The first randomised answer for atrial fibrillation with a single stroke risk factor, and it favours anticoagulating. Fewer than 20 primary events across 1,803 patients carry the result: the interval runs to 0.94, so the direction is firmer than the size. Open-label at 18 Korean centres, with an observed event rate far below the planning assumption and an absolute difference of one percentage point.

Discuté dans des podcasts